Evidence map›Paper›PMID 41040255›Full record

ArticlebioRxiv : the preprint server for biology2025

Mechanisms of superior respiratory IgA responses against SARS-CoV-2 after mucosal vaccination.

Jinyi Tang, Arka Sen Chaudhuri, Panke Qu, Pei Li, Yajie Liu, Yue Wu, Kristin Wavell, MarthaJoy M Spano, In Su Cheon, Chaofan Li and 21 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Jinyi TangBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA 22908.
Arka Sen ChaudhuriBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA 22908.
Panke QuCenter for Retrovirus Research, The Ohio State University, Columbus, OH, USA 43210.
Pei LiCenter for Retrovirus Research, The Ohio State University, Columbus, OH, USA 43210.
Yajie LiuCenter for Retrovirus Research, The Ohio State University, Columbus, OH, USA 43210.
Yue WuBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA 22908.
Kristin WavellChild Health Research Center, Department of Pediatrics, University of Virginia, Charlottesville, VA, USA 22908.
MarthaJoy M SpanoDivision of Asthma, Allergy and Immunology, Department of Medicine, University of Virginia, Charlottesville, VA, USA 22908.
In Su CheonBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA 22908.
Chaofan LiBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA 22908.
Jane YuBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA 22908.
Harish NarasimhanBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA 22908.
Mohd ArishBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA 22908.
Wei QianBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA 22908.
Gislane de Almeida SantosBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA 22908.
Samuel P YoungBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA 22908.
Anika AgarwalBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA 22908.
Fangming ZhuDepartment of Microbiology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA 35294.
Takao KobayashiDivision of Allergy, Asthma, and Clinical Immunology, Mayo Clinic Arizona, Scottsdale, AZ USA, 85259.
Maria VelegrakiPelotonia Institute for Immuno-Oncology (PIIO), The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC), Columbus, OH, USA 43210.
Mark H KaplanDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA 46074.
Justin J TaylorBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA 22908.
Guizhi ZhuDepartment of Pharmaceutical Sciences, College of Pharmacy, Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA, 48109.
Haitao HuDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA 77555.
Zihai LiPelotonia Institute for Immuno-Oncology (PIIO), The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC), Columbus, OH, USA 43210.
Hui HuDepartment of Microbiology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA 35294.
Hirohito KitaDivision of Allergy, Asthma, and Clinical Immunology, Mayo Clinic Arizona, Scottsdale, AZ USA, 85259.
Nu ZhangDepartment of Microbiology, Immunology and Molecular Genetics, Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA 78229.
Shan-Lu LiuCenter for Retrovirus Research, The Ohio State University, Columbus, OH, USA 43210.
W Gerald TeagueBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA 22908.
Jie SunBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA 22908.ORCID 0000-0002-2347-4511

Funding

Cancer Research Training Program: From Molecular Mechanisms to Therapeutic StrategiesT32CA009109 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Andrew Carl Dudley, Melanie R Rutkowski · 1985 to 2026
$13.9M
Project 3: Responding to Changing Serological and Viral Information around COVID-19 (RESPOND)U54CA260582 · NCI · OHIO STATE UNIVERSITY · PI MCALEARNEY, ANN SCHECK, OLTZ, EUGENE M · 2020 to 2024
$10.4M
INTERDISCIPLINARY TRAINING PROGRAM IN IMMUNOLOGYT32AI007496 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Michael G. Brown, Coleen A McNamara · 1995 to 2026
$10.2M
Host cellular network governing the development of post SARS-CoV-2 tissue sequelaeR01AI147394 · NIAID · UNIVERSITY OF VIRGINIA · PI Jie Sun · 2020 to 2026
$4.7M
Molecular regulation of protective CD8 immunity against influenza infectionR01AI112844 · NIAID · UNIVERSITY OF VIRGINIA · PI SUN, JIE · 2015 to 2024
$4.5M
Elucidating the roles of alveolar macrophage inflammation and selfrenewal during influenza infectionR01AG069264 · NIA · UNIVERSITY OF VIRGINIA · PI Jie Sun · 2020 to 2026
$3.5M
Roles of tissue-resident helper T cells in mucosal immunity against influenzainfectionR01AI154598 · NIAID · UNIVERSITY OF VIRGINIA · PI SUN, JIE · 2020 to 2024
$2.9M
Determinants of Convalescent and Vaccine-induced Mucosal Specific Immunity to SARS-CoV-2 and Variants of Concern in Children with AsthmaR01AI176171 · NIAID · UNIVERSITY OF VIRGINIA · PI Jie Sun, WILLIAM GERALD TEAGUE · 2023 to 2026
$2.7M
Uncover mechanisms underlying the development of chronic lung sequelae post COVID-19R01HL170961 · NHLBI · UNIVERSITY OF VIRGINIA · PI Jie Sun, ROBERT VASSALLO · 2023 to 2026
$2.7M
Small Circular mRNA VaccinesR01AI168684 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI ZHU, GUIZHI · 2022 to 2025
$2.2M
Sony MA900 Cell SorterS10OD028518 · OD · UNIVERSITY OF VIRGINIA · PI BENDER, TIMOTHY P. · 2020 to 2020
$359k
Immune-epithelial progenitor interactions drive age-associated dysplastic lung repair post viral pneumoniaF31HL170746 · NHLBI · UNIVERSITY OF VIRGINIA · PI NARASIMHAN, HARISH · 2023 to 2024
$86k
NCI NIH HHS T32 CA009109NCI NIH HHS U54 CA260582NHLBI NIH HHS F31 HL170746NHLBI NIH HHS R01 HL170961NIAID NIH HHS R01 AI112844NIAID NIH HHS R01 AI147394NIAID NIH HHS R01 AI154598NIAID NIH HHS R01 AI168684NIAID NIH HHS R01 AI176171NIAID NIH HHS T32 AI007496NIA NIH HHS R01 AG069264NIH HHS S10 OD028518
6 · The paper itself

Abstract

Mucosal immunization and respiratory IgA offer significant promise in protecting against airborne pathogens, including SARS-CoV-2. However, the conditions and mechanisms that lead to the robust induction of respiratory IgA responses following mucosal vaccination remain poorly understood. It is also currently debatable whether mucosal vaccination is still warranted given that most individuals in developed countries have established a hybrid immunity from vaccination and infection. Here we characterized respiratory mucosal immune responses after SARS-CoV-2 infection, vaccination or both in humans. We found that hybrid immunity resulted in moderately increased respiratory IgA and neutralizing antibody responses compared to infection or vaccination alone. However, a direct comparison of hybrid immunity and a mucosal adenovirus-based booster vaccination in animal models revealed that respiratory booster immunization elicited markedly stronger and more durable respiratory IgA, T cell response, and protective immunity against SARS-CoV-2, supporting the promise of respiratory mucosal vaccination. Mechanistically, we found that mucosal booster immunization induced local IgA-secreting cells in the respiratory mucosa, aided by pulmonary CD4

Identifiers

PMID41040255
PMCPMC12485830

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.